GSK

GSKHealthcare
1,360.00GBX
0.15%
Market Cap
56.06B
Volume
7.98M
74% of avg
P/E Ratio
8.10
EPS (TTM)
1.68
Beta
0.27
Day Range
1,354.56p - 1,384.50p
52 Week Range
1,242.50p1,360.00p1,823.50p
1,360.00p

Upcoming Events

Summer 2025
Vaccine doses will be ready for use in the US
June 2025
Regulatory Submission
High Impact Event
20 June 2025
FDA Decision on Shingrix Prefilled Syringe
High Impact Event
H2 2025
US commercial launch of Blujepa
High Impact Event
10 July 2025
Q1 2025 dividend payment
23 July 2025
US FDA decision expected on Blenrep combinations
High Impact Event
1 August 2025
H1 2025 Results Release
High Impact Event
September 1, 2025
Regulatory filing for depemokimab in CRSwNP
High Impact Event
September 2025
Annual Results Release
High Impact Event
Q4 2025
Full year 2025 results announcement
High Impact Event
December 2025
Potential Regulatory Approval
High Impact Event
December 16, 2025
PDUFA date for FDA review of depemokimab submissions
High Impact Event
Q1 2026
Potential EMA approval for new Shingrix prefilled syringe presentation
2026
Potential approval and launch of depemokimab for CRSwNP
High Impact Event
2029
First launch of efimosfermin expected
High Impact Event
2034
End of extended exclusive rights for Zhifei to commercialize Shingrix in China
High Impact Event
GSK
NEUTRAL

GSK to acquire efimosfermin, a potential best-in-class specialty medicine for steatotic liver disease

The healthcare company has agreed to acquire a phase III-ready specialty medicine to treat a form of liver disease, expanding its pipeline of liver disease treatments.

GSK
NEUTRAL

GSK Directors Increase Shareholdings

The healthcare company's directors have acquired additional ordinary shares through the firm's employee share plan.

GSK
BAD

GSK Ends Belrestotug Development Programme After Phase 2 Failure

The biopharma company is ending the development of an anti-TIGIT monoclonal antibody after interim analyses showed the drug did not meet efficacy targets in phase 2 trials.

GSK
NEUTRAL

GSK CEO Granted Top-Up Performance Share Award

The healthcare company has granted its CEO a top-up conditional share award under the firm's performance share plan.

GSK
NEUTRAL

GSK Announces Director/PDMR Shareholding

The healthcare company has announced a director's shareholding transaction.

GSK
GOOD

GSK's Linerixibat Meets Primary Endpoint in PBC Pruritus Trial

The pharmaceutical company announced positive results from a phase III trial of its drug linerixibat for treating cholestatic pruritus in primary biliary cholangitis patients.

GSK
NEUTRAL

GSK Announces Director Appointment

The healthcare company has announced the appointment of a new director to its board.

GSK
NEUTRAL

GSK's Nucala shows promise in reducing COPD exacerbations

The pharmaceutical company reports positive results from a phase III trial of its Nucala drug in treating chronic obstructive pulmonary disease.

GSK
GOOD

GSK Reports Strong Q1 2025 Results, Reaffirms Full-Year Guidance

The major pharmaceutical company reported solid Q1 2025 results, with moderate revenue growth and strong cash generation. The firm reaffirmed its full-year guidance, signaling confidence in its performance.

GSK
GOOD

GSK's Blenrep Combinations Approved by UK MHRA for Relapsed/Refractory Multiple Myeloma

The healthcare company has received UK regulatory approval for its Blenrep combinations to treat relapsed/refractory multiple myeloma, marking the first such approval globally.